Omni Bio Pharmaceutical, a biopharmaceutical company focused on the commercialization of novel uses of alpha-1 antitrypsin (AAT), today reported study results for the company’s recombinant molecule, Fc-AAT, suggesting its potential to treat refractory gout and other inflammatory conditions.
Leo A. B. Joosten, PhD, of the Radboud University Medical Center, Nijmegen, The Netherlands, detailed the findings of several of his studies in mouse models of gouty arthritis, which showed that Fc-AAT:
• Suppressed pro-inflammatory responses
• Exhibited a reduction of 85% in these parameters at a relatively low dose of 50 µg (2 mg/kg per mouse) that was at least as effective as a high dose (10mg/mouse) of the IL1 receptor antagonist anakinra
• Was at least 40 times more potent than a clinical grade of plasma-derived AAT
• Exhibited a prolonged duration of action relative to plasma-derived AAT
Additionally, the study also demonstrated Fc-AAT’s unique mechanism of anti-inflammatory action that occurs through modulation of TLR2 and TLR4 expression, suppression of a variety of pro-inflammatory cytokine mediators, inhibition of capsase-1 activation, and induction of IL1 receptor antagonism.
“These results are very exciting and suggest that Fc-AAT has high potential for use in the treatment of refractory gout and other inflammatory conditions. We are now considering how best to pursue early clinical trials in patients suffering from this condition,” Dr. Joosten stated in the press release.
While current treatments require that AAT-deficient patients travel to a doctor’s office or infusion center for weekly intravenous infusions, Omni Bio’s treatment option in the future may be available for self-administration.
“Findings such as these continue to validate the broad potential for the use of AAT in several inflammatory conditions and also highlight the potential for our recombinant Fc fusion molecule to be used in a low-dose, self-administered subcutaneous format,” Omni Bio’s Chief Scientific Officer Dr. Charles Dinarello stated.
For more information, visit www.omnibiopharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment